The treatment of type 2 diabetes in the presence of renal impairment: What we should know about newer therapies

Clinical Pharmacology: Advances and Applications

Volumn 8, Issue , 2016, Pages 61-81

  Davies, Melanie ^a,b   Chatterjee, Sudesna ^a,b   Khunti, Kamlesh ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Chronic kidney disease; DPP IV inhibitor; GLP 1RA; PK; Renal impairment; SGLT 2 inhibitor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALBUMIN; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN DERIVATIVE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; MEGLITINIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN;

ACUTE PANCREATITIS; ALBUMIN URINE LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; TREATMENT OUTCOME;

EID: 84992107531     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S82008     Document Type: Review

References (142)

1. Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney disease. Blood Purif. 2011;31(1–3):138–145.
2. Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc. 2014;125:229–243; discussion 243–246.
3. Tedla FM, Brar A, Browne R, Brown C. Hypertension in chronic kidney disease: navigating the evidence. Int J Hypertens. 2011;2011:132405.
4. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol. 2013;45(6):1605–1612.
5. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883.
6. Savarese G, Dei Cas A, Rosano G, et al. Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. Int J Cardiol. 2014;172(2):403–410.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–163.
8. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–682.
9. Hippisley-Cox J, Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract. 2010;11:49.
10. Fowler MJ. Microvascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.
11. International Diabetes Federation. IDF Diabetes Atlas. 7th edn. Brussels, Belgium: International Diabetes Federation; 2015.
12. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care. 2013;36(Suppl 2): S120–S126.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
14. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–523.
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393.
16. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35–e48.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
18. Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol. 2005;16(Suppl 1):S7–S10.
19. Cavanaugh K. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25(3):90–97.
20. Takeda. Actos (pioglitazone) Summary of Product Characteristics; 2014. Available from: https://www.medicines.org.uk/emc/medicine/4236. Accessed November 2015.
21. Merck Serono. Glucophage (metformin) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/1043. Accessed November 2015.
22. Pfizer Limited. Minodiab (glipizide) Summary of Product Characteristics; 2014. Available from: https://www.medicines.org.uk/emc/medicine/9851. Accessed November 2015.
23. Wockhardt UK Limited. Glibenclamide Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/30411. Accessed November 2015.
24. Wockhardt UK Limited. Gliclazide Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/27762. Accessed November 2015.
25. Accord Healthcare Limited. Glimepiride Summary of Product Characteristics. 2014. Available from: https://www.medicines.org.uk/emc/medicine/25813. Accessed November 2015.
26. Novo Nordisk Limited. Prandin (repaglinide) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/18980. Accessed November 2015.
27. Eli Lilly and Company Limited. Humulin I (isophane insulin) Summary of Product Characteristics; 2015. Available from: https://www. medicines.org.uk/emc/medicine/3425. Accessed November 2015.
28. Sanofi-aventis. Lantus (insulin glargine) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/25506. Accessed November 2015.
29. Novo Nordisk Limited. Levemir (insulin detemir) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/14584. Accessed November 2015.
30. Novo Nordisk Limited. Tresiba (insulin degludec) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/27360. Accessed November 2015.
31. Eli Lilly and Company Limited. Humalog (insulin lispro) Summary of Product Characteristics; 2014. Available from: https://www.medicines. org.uk/emc/medicine/30005. Accessed November 2015.
32. Sanofi. Apidra (insulin glulisine) Summary of Product Characteristics; 2013. Available from: https://www.medicines.org.uk/emc/medicine/26476. Accessed November 2015.
33. Novo Nordisk Limited. NovoMix (insulin aspart) Summary of Product Characteristics; 2014. Available from: https://www.medicines.org.uk/emc/medicine/8591. Accessed November 2015.
34. Actavis UK Ltd. Acarbose Summary of Product Characteristics; 2013. Available from: https://www.medicines.org.uk/emc/medicine/27829. Accessed February 2016.
35. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21(10):1659–1663.
36. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.
37. National Institute for Health and Care Excellence (NICE). [The management of type 2 diabetes (CG87)]. London: National Institute for Clinical Excellence [Published May 2009]. Available from: http://guidance.nice. org.uk/cg87. Accessed June 16, 2015.
38. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675.
39. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5): 850–886.
40. Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 2008;31(10):839–850.
41. Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. P T. 2009;34(9):490–501.
42. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes. 2012;5:357–367.
43. AstraZeneca AB. Symlin (pramlintide acetate) Prescribing Information; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021332s025lbl.pdf. Accessed February 2016.
44. Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(4):789–794.
45. VeroScience. Cycloset (bromocriptine) Prescribing Information; 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf. Accessed February 2016.
46. Sanofi. Toujeo (insulin glargine) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/30586. Accessed November 2015.
47. Simpson D, McCormack PL, Keating GM, Lyseng-Williamson KA. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs. 2007;67(3):407–434.
48. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005;37(11):702–707.
49. Owens D, Vora J. Insulin aspart: a review. Expert Opin Drug Metab Toxicol. 2006;2(5):793–804.
50. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608–624.
51. Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin glargine: a review 8 years after its introduction. Expert Opin Pharmacother. 2009;10(4):705–718.
52. Iglesias P, Diez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10(10):811–823.
53. Jacobsen L, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45:A259–A260.
54. Kiss I, Arold G, Roepstorff C, Bottcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175–183.
55. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60(5):469–476.
56. Merck Sharp and Dohme Limited. Januvia (sitagliptin) Summary of Product Characteristics; 2015. Available from: https://www.medicines. org.uk/emc/medicine/19609. Accessed November 2015.
57. Novartis Pharmaceuticals UK Ltd. Galvus (vildagliptin) Summary of Product Characteristics; 2016. Available from: https://www.medicines. org.uk/emc/medicine/20734. Accessed January 2016.
58. AstraZeneca UK Limited. Onglyza (saxagliptin) Summary of Product Characteristics. 2015; Available from: https://www.medicines.org.uk/emc/medicine/22315. Accessed February 2016.
59. Boehringer Ingelheim Limited. Trajenta (linagliptin) Summary of Product Characteristics; 2014. Available from: https://www.medicines. org.uk/emc/medicine/25000. Accessed November 2015.
60. Takeda UK Ltd. Vipidia (alogliptin) Summary of product characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/28513. Accessed November 2015.
61. AstraZeneca UK Limited. Byetta (exenatide) Summary of Product Characteristics. 2016. Available from: https://www.medicines.org.uk/emc/medicine/19257. Accessed January 2016.
62. AstraZeneca UK Limited. Bydureon (exenatide) Summary of Product Characteristics; 2016. Available from: https://www.medicines.org.uk/emc/medicine/24665. Accessed February 2016.
63. Sanofi-aventis. Lyxumia (lixisenatide) Summary of Product Characteristics; 2014. Available from: https://www.medicines.org.uk/emc/medicine/27405. Accessed November 2015.
64. Novo Nordisk Limited. Victoza (liraglutide) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/21986. Accessed November 2015.
65. GlaxoSmithKline Trading Services Limited. Eperzan (albiglutide) Summary of Product Characteristics; 2016. Available from: https://www.medicines.org.uk/emc/medicine/31399. Accessed February 2016.
66. Eli Lilly and Company Limited. Trulicity (dulaglutide) Summary of Product Characteristics; 2016. Available from: https://www.medicines. org.uk/emc/medicine/29747. Accessed February 2016.
67. AstraZeneca UK Limited. Forxiga (dapagliflozin) Summary of Product Characteristics; 2014 Available from: https://www.medicines.org.uk/emc/medicine/27188. Accessed November 2015.
68. Janssen-Cilag Ltd. Invokana (canagliflozin) Summary of Product Characteristics; 2015. Available from: https://www.medicines.org.uk/emc/medicine/28400. Accessed February 2016.
69. Boehringer Ingelheim Limited. Jardiance (empagliflozin) Summary of Product Characteristics; 2015. Available from: https://www.medicines. org.uk/emc/medicine/28973. Accessed November 2015.
70. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10(2):88–103.
71. Cheng D, Fei Y, Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One. 2014;9(10):e111543.
72. Game F. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease. Nephron Clin Pract. 2014;126(1):14–18.
73. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206.
74. Tricco AC, Antony J, Khan PA, et al. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014;4(12):e005752.
75. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–523.
76. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1): 7–18.
77. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862–1864.
78. He YL, Flannery B, Wang Y et al. The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86). Clin Pharmacol Ther. 2007;81(Suppl 1):S113.
79. He YL, Kulmatycki K, Zhang Y, et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther. 2013;51(9):693–703.
80. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011;50(4):253–265.
81. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13(10):939–946.
82. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P). Diabetes. 2008;57(Suppl 1):A160.
83. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3): 232–242.
84. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(3):313–319.
85. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37(3):536–544.
86. Watanabe M, Furuya F, Kobayashi T. DPP-4 inhibitor vildagliptin reduces urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Endocrine Abstracts. 2012;29:P687.
87. Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38(4):696–705.
88. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–3468.
89. Dineen L, Law C, Scher R, Pyon E. Alogliptin (nesina) for adults with type-2 diabetes. P T. 2014;39(3):186–202.
90. Sakata K, Hayakawa M, Yano Y, et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev. 2013;29(8):624–630.
91. Ahren B. The future of incretin-based therapy: novel avenues – novel targets. Diabetes Obes Metab. 2011;13(Suppl 1):158–166.
92. Kuritzky L, Umpierrez G, Ekoe JM, Mancillas-Adame L, Lando LF. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014; 126(6):60–72.
93. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19–28.
94. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.
95. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
96. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 2012;35(6):483–488.
97. Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231(1): 57–61.
98. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007; 64(3):317–327.
99. Liu Y, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (abstract). Diabetes. 2009;59:A149–A150.
100. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905.
101. Loghin C, de la Peña A, Cui X, Zhang X, Geiser JS, Chien JY. Pharmacokinetics of once weekly dulaglutide in special populations. Diabetologia. 2014;57:(Suppl 1):S349.
102. Young MA, Wald JA, Matthews JE, Yang F, Reinhardt RR. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. Postgrad Med. 2014;126(3):35–46.
103. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146(4):2069–2076.
104. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011;6:67–79.
105. Zavattaro M, Caputo M, Sama MT, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620–626.
106. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care. 2016;39(2):222–230.
107. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011; 34(Suppl 2):S279–284.
108. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–4817.
109. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3):671–681.
110. Chao EC. SGLT-2 inhibitors: A new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4–11.
111. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8): 495–502.
112. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8: 1335–1380.
113. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693.
114. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432–444.
115. Stein P, Berg JK, Morrow L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014;63(10):1296–1303.
116. Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), a novel oral agent for type-2 diabetes. P T. 2013;38(11):656–666.
117. Inagaki N, Kondo K, Yoshinari T, et al. Pharmacokinetic and pharma-codynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Investig. 2014;34(10):731–742.
118. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215–222.
119. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–526.
120. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403–411.
121. Inagaki N, Kondo K, Yoshinari T, et al. Pharmacokinetic and pharma-codynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. Clin Drug Investig. 2014;34(10):731–742.
122. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971.
123. Barnett AH, Mithal A, Manassie J, et al; EMPA-REG Renal Trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–384.
124. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
125. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
126. University College Dublin. The differential effects of diabetes therapy on inflammation. Available from: https://clinicaltrials.gov/ct2/show/NCT02150707?term=NCT02150707&rank=1. NLM identifier: NCT02150707. Accessed September 30, 2015.
127. Boehringer Ingelheim. Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA). Available from: https://clinicaltrials.gov/ct2/show/NCT01897532?term=NCT01897532&rank=1. NLM identifier: NCT01897532. Accessed September 30, 2015.
128. Boehringer Ingelheim. MARLINA – T2D: Efficacy, Safety and Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01792518. NLM identifier: NCT01792518. Accessed November 30, 2015.
129. VU University Medical Center. Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS). Available from: https://clinicaltrials.gov/ct2/show/NCT02106104?term=NCT02106104& rank=1. NLM identifier: NCT02106104. Accessed November 30, 2015.
130. Profil Institut für Stoffwechselforschung GmbH. Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment. Available from: https://clinicaltrials.gov/ct2/show/NCT01903070? term=NCT01903070&rank=1. NLM identifier: NCT01903070. Accessed November 30, 2015.
131. Bristol-Myers Squibb. Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments. Available from: https://clinicaltrials.gov/ct2/show/NCT01377935?term= Comparison+of+Risk+of+Hospitalization+for+Acute+Kidney+ Injury+Between+Patients+With+Type+2+Diabetes+Initiating+ Saxagliptin&rank=1. NLM identifier: NCT01377935. Accessed November 30, 2015.
132. Baylor Research Institute. Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome. Available from: https://clinicaltrials.gov/ct2/show/NCT02251431. NLM identifier: NCT02251431. Accessed November 30, 2015.
133. VU University Medical Center. Effect of LIXIsenatide on the Renal System (ELIXIRS). Available from: https://clinicaltrials.gov/ct2/show/NCT02276196. NLM identifier: NCT02276196. Accessed November 30, 2015.
134. Karl Neff, University College Dublin. The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01847313? term=The+Effect+of+Glucagon-like-peptide+1+%28GLP-1%29+ Receptor+Agonism+on+Diabetic+Kidney+Disease&rank=1. NLM identifier: NCT01847313. Accessed November 30, 2015.
135. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546.
136. AstraZeneca AB. Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE). Available from: https://clinicaltrials.gov/ct2/show/NCT02413398?term=Study+to+Evaluate+the+Effect+of+ Dapagliflozin+on+Blood+Glucose+Level+and+Renal+Safety+ in+Patients+With+Type+2+Diabetes&rank=1. NLM identifier: NCT02413398. Accessed November 30, 2015.
137. Janssen Research and Development, LLC. A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R). Available from: https://clinicaltrials.gov/ct2/show/record/NCT01989754. NLM identifier: NCT01989754. Accessed November 30, 2015.
138. Janssen Research and Development, LLC. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE). Available from: https://clinicaltrials.gov/ct2/show/NCT02065791?term=NCT02065791& rank=1. NLM identifier: NCT02065791. Accessed November 30, 2015.
139. Boehringer Ingelheim. Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls. Available from: https://clinicaltrials.gov/ct2/show/NCT01867307?term=Effect+of+Empagliflozin+Kinetics+on+Renal+ Glucose+Reabsorption+in+Patients+With+Type+II+Diabetes+and+ Healthy+Controls&rank=1. NLM identifier: NCT01867307. Accessed November 30, 2015.
140. Groop PH, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16(6):560–568.
141. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654–662.
142. Clementi A, Virzi GM, Goh CY, et al. Cardiorenal syndrome type 4: a review. Cardiorenal Med. 2013;3(1):63–70.